IPP Bureau
USFDA refuses to grant EUA to Covaxin for padeatric use
By IPP Bureau - March 04, 2022
Covaxin is not approved in the USA for any age group
MIBCON NDC offers CO2 Optimisation module
By IPP Bureau - March 04, 2022
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Govt announces over Rs 100 crore investment for Ayush sector in Nagaland
By IPP Bureau - March 04, 2022
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases
By IPP Bureau - March 03, 2022
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Cipla gets approval from SEC to conduct Paxlovid trials
By IPP Bureau - March 03, 2022
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Brinton ties up with Scholl Wellness Company
By IPP Bureau - March 03, 2022
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
IIFL AMC funds acquire stake in OmniActive Health Technologies
By IPP Bureau - March 03, 2022
OmniActive seeks to improve lives by enhancing nutrition and wellness through science and innovation
Limited impact of short-term disruptions, growth momentum to continue in FY 23
By IPP Bureau - March 03, 2022
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
IHub-Data and IIIT-Hyderabad offer course on drug discovery
By IPP Bureau - March 03, 2022
12-week certificate course commences on March 10th 2022
WHO includes molnupiravir in its Covid-19 treatment guidelines
By IPP Bureau - March 03, 2022
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
By IPP Bureau - March 03, 2022
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Lupin receives USFDA approval for topical solution
By IPP Bureau - March 03, 2022
The product will be manufactured at Lupin’s facility in Pithampur, India
Medix Biochemica announces expansion of its porfolio
By IPP Bureau - March 03, 2022
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Masina Hospital opens a new dialysis centre
By IPP Bureau - March 03, 2022
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
Merck KGaA reports higher profits on strong volumes across its businesses
By IPP Bureau - March 03, 2022
Company expects strong organic growth in sales, EBITDA in 2022
